Guillain-Barré syndrome (GBS) is rare autoimmune polyneuropathy that is infrequently seen in the post-transplant population, presumably due to the presence of immunosuppression. When it does occur in this setting, Cytomegalovirus (CMV) infection is a common inciting factor. Treatment modalities for GBS include intravenous immunoglobulin (IVIg) or plasmapheresis. Rarely, IVIg infusion has been associated with myocardial infarction. We describe a case of a patient status post heart transplantation who presented with GBS shortly after developing CMV viremia. When treatment with IVIg was initiated, our patient developed myocardial infarction with acute cardiac biomarker elevation, acute systolic dysfunction, and cardiogenic shock requiring inotropic and vasopressor support. Coronary angiography demonstrated no significant coronary artery disease. The patient's cardiac function recovered, as did the GBS following initiation of plasmapheresis. We review prior cases of GBS in transplant patients as well as IVIg associated myocardial infarction.
Conclusion: Conversion to sirolimus is associated with improved renal function in patients developing AKI while on tacrolimus. Longer follow up is needed to determine the impact of sirolimus conversion on the cumulative incidence of GvHD. There is a need for prospective studies to address the feasibility of calcineurin-free GvHD prophylaxis in SCT.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.